Connecting clinical care, data and research
PartnershipsContact
← Back to publications

RESEARCH PUBLICATION / 2025

Original Article

Comparison of cardiovascular and venous thrombosis in different psoriasis diseases biologic agents

Risk of major adverse cardiovascular events and venous thromboembolic events between patients with psoriasis or psoriatic arthritis on tumor necrosis factor inhibitors, interleukin 17 inhibitors, interleukin 12/23 inhibitors, and interleukin 23 inhibitors: An emulated target trial analysis.

Journal of the American Academy of Dermatology

Citation & Authors

J Am Acad Dermatol. 2025;92(5):1015-1023.

Tai-Li Chen; Jing-Yang Huang; Hui-Yun Lin; Yun-Ting Chang; Cheng-Yuan Li; James Cheng-Chung Wei

ABSTRACT · RESEARCH SUMMARY

Research summary

The study included 32,098 biologic-naive patients with psoriasis or psoriatic arthritis and used target trial emulation to compare IL-17, IL-12/23, IL-23, and TNF inhibitors. Overall risks of major adverse cardiovascular events and venous thromboembolism did not differ significantly, although differences appeared in some metabolic comorbidity subgroups. Psoriasis severity was unavailable, and unmeasured confounding must be considered.

Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗